Analyst Reco. Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
39.91 ^USD	+0.23%		+3.47%	+7.98%

04-25	Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	CI
04-18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	04-18	MT
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating	02-21	MT
Goldman Sachs Cuts Halozyme Therapeutics' Price Target to $40 From $45, Keeps Neutral Rating	01-18	MT
HC Wainwright Cuts Halozyme Therapeutics Price Target to $48 From $61, Maintains Buy Rating	01-18	MT
Morgan Stanley Cuts Halozyme Therapeutics Price Target to $59 From $61, Maintains Overweight Rating	12-26	MT
HC Wainwright Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Buy Rating	19/10/23	MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Overweight Rating	10/08/23	MT
Goldman Sachs Downgrades Halozyme Therapeutics to Neutral From Buy, Raises Price Target to $45 From $43	24/07/23	MT
HC Wainwright Starts Halozyme Therapeutics at Buy With $61 Price Target	24/07/23	MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $60 From $64, Maintains Overweight Rating	10/05/23	MT
Piper Sandler Upgrades Halozyme Therapeutics to Overweight From Neutral With $46 Price Target	10/05/23	MT
Berenberg Bank Resumes Coverage on Halozyme Therapeutics With Buy Rating, $58 Price Target	27/03/23	MT
Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $48 From $55, Maintains Overweight Rating	17/03/23	MT
Wells Fargo Adjusts Halozyme Therapeutics' Price Target to $55 From $65, Keeps Overweight Rating	16/03/23	MT
SVB Securities Downgrades Halozyme Therapeutics to Market Perform From Outperform, Price Target is $42	16/03/23	MT
Morgan Stanley Adjusts Halozyme Therapeutics Price Target to $64 From $65, Maintains Overweight Rating	06/03/23	MT
JPMorgan Adjusts Price Target on Halozyme Therapeutics to $52 From $54, Maintains Overweight Rating	23/02/23	MT
JMP Securities Adjusts Price Target on Halozyme Therapeutics to $66 From $62, Maintains Market Outperform Rating	22/02/23	MT
Morgan Stanley Assumes Halozyme Therapeutics at Overweight Rating, Adjusts Price Target to $65 From $53	21/12/22	MT
Benchmark Adjusts Price Target on Halozyme Therapeutics to $68 From $55, Maintains Buy Rating	08/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Analyst Reco.

Filters